Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication

Williams CG, Silvas JA, Jureka AS, Nicolini AM, Chvatal SA, Carlson-Strevermer J, Oki J, Holden K, Basler CF.

Cell Reports, 2021


Therapeutic small molecule inhibitor treatments targeting SARS coronavirus 2 (SARS-CoV-2) were evaluated as antiviral treatment.  Treatments included VPS34, Orlistat, and Triacsin C.  Of these treatments, VPS34 showed the most potent anti-viral activity.